infrainfra
Diamond
- Joined
- Oct 14, 2025
- Posts
- 1,388
- Reputation
- 754
@exsttttt thoughtsI've been noticing many threads on taking FGFR(3) inhibitors recently, and I think many of these users have barely done any research;
At first, I felt like there are only studies and case studies for those with fgfr3 over-expression to inhibit it to normal (hence taller height), I'm not sure how making it underexpressed would yield a beneficial effect on height (an "worth it" effect) which is desirable or significant
Besides, FGFR3 is a brake for growth, it exists for a reason as it stops cartilage from becoming into bone. Inhibiting it to lower-than-normal makes me skeptic about possible deformation, or side effects. You'd be growing uncontrollably, unideal to your cells which are not perfect and will easily mess up.
Just look at children who used FGFR3 inhibitors, 42% of them develop SCFE, considered a medical emergency.
Erdafitinib had to be discontinued due to the patient's unusual rapid growth over the 9 months of therapy, severe kyphoscoliosis, and spinal cord compression with cervical myelopathy. The patient grew a total of 14.3 cm, or at an annualized growth of 19.06 cm (normal growth is ∼10 cm per year for a 15-year-old male).Slipped capital femoral epiphyses: a major on target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients - PMC
FGFR tyrosine kinase inhibitors (TKIs) are increasingly being used off label in pediatrics. Long term safety data is limited, and serious toxicities unique to pediatrics may emerge. In a retrospective analysis of patients<18 years of age with ...pmc.ncbi.nlm.nih.gov
https://pmc.ncbi.nlm.nih.gov/articles/PMC11152661/#:~:text=e-,rdafitinib had to be,15-year-old male).,-Growth
View attachment 5196212Infigratinib, a Selective FGFR1-3 Tyrosine Kinase Inhibitor, Alters Dentoalveolar Development at High Doses - PMC
Fibroblast Growth Factor Receptor-3 (FGFR3) gain-of-function mutations are linked to achondroplasia. Infigratinib, a FGFR1-3 tyrosine kinase inhibitor, improves skeletal growth in an achondroplasia mouse model. FGFs and their receptors have critical ...
You may argue that this was a small group size of 7 patients, but, SCFE is an extremely rare condition, 3/7 which means this cannot be coincidence.
Impressively, one individual went from 170cm to 200cm in just 150 weeks, which is notable.
I assume you will not be using these in short cycles, as we've seen 50 weeks resulting in SCFE yet achieving 13cm of height
Another instance, those with congenital FGFR UNDERexpression usually grow tall but have deformities such as kyphosis, permanently bent fingers, etc; this is called CATSHL syndrome which makes you unusually tall while causing loss of function and making bones too long.
Is it really worth the height growth it gives you?
They also look similar to those who are marfanoid;
View attachment 5196227
so i'm not sure how practical it would be inhibiting it and if the stature gained from this is beneficial or desirable.
I'd like to see anyone that makes an FGFR3 thread countering these questions, which I'm looking forward to see if he'll bring something new to the table and address the dilemma's, especially the fact that some users contemplate Pan-FGFR inhibitors which would be egregious (case studies show fgfr1/2/3/4 inhibited yet caused a deformity, what would a pan-fgfr inhibitor do?)
@Vireon @anondude @N1kolai @81xa @chang cypionate
